PMID- 30105954 OWN - NLM STAT- MEDLINE DCOM- 20190225 LR - 20240330 IS - 1535-3699 (Electronic) IS - 1535-3702 (Print) IS - 1535-3699 (Linking) VI - 243 IP - 11 DP - 2018 Jul TI - Nuclear factor erythroid 2-related factor 2 activation mediates hyperhomocysteinemia-associated lipolysis suppression in adipocytes. PG - 926-933 LID - 10.1177/1535370218788520 [doi] AB - Hyperhomocysteinemia (HHcy) is associated with suppressed lipolytic response in adipocytes/adipose tissue, however, the underlying mechanism remains to be extensively studied. Nuclear factor erythroid 2-related factor 2 (Nrf2), a master transcriptional factor regulating antioxidant generation, has been recently reported to mediate lipid metabolism. Employing both fully differentiated 3T3-L1 adipocytes and male C57BL/6 mice, in the present study, we investigated the potential involvement of Nrf2 activation in HHcy-mediated lipolytic suppression. Our results showed that homocysteine (Hcy) treatment resulted in suppressed lipolysis, evidenced by increased intracellular triglyceride (TG) accumulation, decreased glycerol and free fatty acid (FFA) in fully differentiated 3T3-L1 adipocytes. Interestingly, Hcy exposure was associated with Nrf2 activation in adipocytes. Further studies showed that Nrf2 knockdown via siRNA transfection ameliorated Hcy-induced glycerol release in adipocytes. On the contrary, Nrf2 activators, epigallocatechin gallate (EGCG) and tert-butylhydroquinone (t-BHQ), increased intracellular TG content and decreased glycerol release in adipocytes. Importantly, our in vitro observations were corroborated by our in vivo findings, in which Hcy feeding (0.1% wt/vol) for four weeks induced Nrf2 expression in adipose tissue and lowered circulating FFA and glycerol levels in mice. Furthermore, EGCG injection (5 mg/kg/d) decreased circulating glycerol levels in comparison to the control group in mice. In conclusion, these results indicated that Nrf2 activation in response to HHcy plays an important role in mediating Hcy-suppressed lipolysis in adipocytes. FAU - Li, Xin AU - Li X AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. FAU - Cheng, Yuhong AU - Cheng Y AD - 2 Daqing Medical College, Daqing 163312, Heilongjiang, P.R. China. FAU - Zhong, Xiuli AU - Zhong X AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. FAU - Zhang, Bing AU - Zhang B AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. FAU - Bao, Zhiwei AU - Bao Z AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. FAU - Zhang, Yi AU - Zhang Y AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. FAU - Wang, Zhigang AU - Wang Z AD - 1 College of Medical Laboratory Science and Technology, Harbin Medical University (Daqing), Daqing 163319, Heilongjiang, P. R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - Exp Biol Med (Maywood) JT - Experimental biology and medicine (Maywood, N.J.) JID - 100973463 RN - 0 (Fatty Acids) RN - 0 (NF-E2-Related Factor 2) RN - 0 (Nfe2l2 protein, mouse) RN - 0 (Triglycerides) RN - 0LVT1QZ0BA (Homocysteine) RN - PDC6A3C0OX (Glycerol) SB - IM MH - 3T3-L1 Cells MH - Adipocytes/drug effects/*metabolism MH - Animals MH - Cytoplasm/chemistry MH - Disease Models, Animal MH - Fatty Acids/analysis MH - Gene Knockdown Techniques MH - Glycerol/analysis MH - Homocysteine/metabolism MH - Hyperhomocysteinemia/*pathology MH - Lipolysis/*drug effects MH - Male MH - Mice MH - Mice, Inbred C57BL MH - NF-E2-Related Factor 2/genetics/*metabolism MH - Triglycerides/analysis PMC - PMC6108053 OTO - NOTNLM OT - 3T3-L1 adipocytes OT - Adipose OT - homocysteine OT - hyperhomocysteinemia OT - lipolysis OT - nuclear factor erythroid 2-related factor 2 EDAT- 2018/08/15 06:00 MHDA- 2019/02/26 06:00 PMCR- 2019/07/01 CRDT- 2018/08/15 06:00 PHST- 2018/08/15 06:00 [entrez] PHST- 2018/08/15 06:00 [pubmed] PHST- 2019/02/26 06:00 [medline] PHST- 2019/07/01 00:00 [pmc-release] AID - 10.1177_1535370218788520 [pii] AID - 10.1177/1535370218788520 [doi] PST - ppublish SO - Exp Biol Med (Maywood). 2018 Jul;243(11):926-933. doi: 10.1177/1535370218788520.